Previous Article | Next Article 
Journal of Virology, April 2001, p. 3988-3992, Vol. 75, No. 8
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.8.3988-3992.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Amino Acid Deletion at Codon 67 and Thr-to-Gly
Change at Codon 69 of Human Immunodeficiency Virus Type 1 Reverse
Transcriptase Confer Novel Drug Resistance Profiles
Tomozumi
Imamichi,1,*
Michael A.
Murphy,1
Hiromi
Imamichi,1 and
H.
Clifford
Lane2
Laboratory of Molecular Retrovirology,
Clinical Services Program, Science Applications International
Corporation
Frederick, National Cancer Institute
Frederick,
Frederick,1 and Laboratory of
Immunoregulation, National Institute of Allergy and Infectious
Diseases, Bethesda,2 Maryland
Received 26 October 2000/Accepted 19 January 2001
The potential roles of an amino acid deletion at codon 67 (
67)
and a Thr-to-Gly change at codon 69 (T69G) in the reverse transcriptase
of human immunodeficiency virus (HIV) type 1 in drug sensitivity and
relative replication fitness were studied. Our results suggest that the
67 and T69G changes can be categorized as mutations associated with
multidrug resistance. The combination of both mutations with an L74I
change (
67+T69G/L74I) leads to a novel 3'-azido-3'-deoxythymidine
resistance motif and compensates for impaired HIV replication.
*
Corresponding author. Mailing address: Laboratory of
Molecular Retrovirology, Clinical Services Program, SAIC
Frederick,
NCI
Frederick, Building 550, Room 126, P.O. Box B, Frederick, MD
21702-1201. Phone: (301) 846-5450. Fax: (301) 846-6762. E-mail:
timamichi{at}nih.gov.
Journal of Virology, April 2001, p. 3988-3992, Vol. 75, No. 8
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.8.3988-3992.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Shahriar, R., Rhee, S.-Y., Liu, T. F., Fessel, W. J., Scarsella, A., Towner, W., Holmes, S. P., Zolopa, A. R., Shafer, R. W.
(2009). Nonpolymorphic Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Treatment-Selected Mutations. Antimicrob. Agents Chemother.
53: 4869-4878
[Abstract]
[Full Text]
-
Villena, C., Prado, J. G., Puertas, M. C., Martinez, M. A., Clotet, B., Ruiz, L., Parkin, N. T., Menendez-Arias, L., Martinez-Picado, J.
(2007). Relative Fitness and Replication Capacity of a Multinucleoside Analogue-Resistant Clinical Human Immunodeficiency Virus Type 1 Isolate with a Deletion of Codon 69 in the Reverse Transcriptase Coding Region. J. Virol.
81: 4713-4721
[Abstract]
[Full Text]
-
Wirden, M., Roquebert, B., Derache, A., Simon, A., Duvivier, C., Ghosn, J., Dominguez, S., Boutonnet, V., Ait-Arkoub, Z., Katlama, C., Calvez, V., Marcelin, A.-G.
(2006). Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients.. Antimicrob. Agents Chemother.
50: 2553-2556
[Abstract]
[Full Text]
-
Winters, M. A., Merigan, T. C.
(2005). Insertions in the Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Genes: Clinical Impact and Molecular Mechanisms. Antimicrob. Agents Chemother.
49: 2575-2582
[Full Text]
-
Boyer, P. L., Imamichi, T., Sarafianos, S. G., Arnold, E., Hughes, S. H.
(2004). Effects of the {Delta}67 Complex of Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase on Nucleoside Analog Excision. J. Virol.
78: 9987-9997
[Abstract]
[Full Text]
-
Shafer, R. W.
(2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev.
15: 247-277
[Abstract]
[Full Text]